Future of BioPharma

The Biopharma industry is an industry dependent oneconomic power of China. China's manufacturing
investment, therefore it is extremely vulnerable toindexes have decreased considerably; however, China
the economic climate. When the economy is boomingstill presents a strong positive growth rate, a large
so is the Biopharma industry, including pharmaceuticalinvestment community, and good cooperation with
consulting firms, life sciences consulting firms, andWestern companies. Right now it is home to more
pharmaceutical sales consulting firms all over thethan 500 Biopharma companies, and is spreading
country. But when the economy is in a downwardthroughout the rest of Asia. India's Biopharma
trend, the biotech industry, not to mention serviceIndustry is growing everyday. Their clinical research
suppliers and vendors, are all affected.rate is growing at a such a staggering rate that soon
In today's bad economy we all know this to be true.they will be in the Top 5 worldwide.
New technologies and product ideas have taken aThese are great signs for the BioPharma industry as
back seat to stock market figures. Serious lay-offs,their growth will be the barometer of their success.
outsourcing, and mergers have cut the industry downAlso, their commitment to innovation will be another
to shreds. Outsourcing has expanded manycrucial factor if this industry strives to stay profitable.
companies' short term sales, but has also abandonedBioPharma companies are starting to spend way
their long term investor equity in the process. Theremore capital in the research of smarter biofuels which
are several powerful trends taking place as weare more economical than wind, solar, and hydro
speak, within the Biopharma industry, as identified byoptions. However, as an increased use in disposables
life sciences consulting firms all across the country.in Biopharma manufacturing is taking place, their
Biopharma product approvals have been slipping formanufacturing departments are diminishing in size as
almost 5 years now, especially recombinant drugs,the need for capacity is decreasing. The Biopharma
however, the next 5 years seem more promising. Asindustry is as strong now as it has ever been, but will
more mergers take place and competition becomesit last the test of time after this economic downturn?
more and more fierce, many companies will need toI guess only time will tell.
restructure or get bought out. This trend will increaseIf you enjoyed this article about life sciences
private funding in the industry, while larger companiesconsulting , please feel free to post it to your site or
will get the rights to market the smaller companies'blog and forward this link to to your friends. Have a
products.great day!
Another trend that has developed is the growingDon't forget to visit our blog.